Key result
CRT reduces HF mortality, with IABP serving as a viable bridge in end-stage disease.
Why the study?
Cardiac resynchronisation therapy reduces symptoms and mortality in chronic heart failure patients with systolic dysfunction and prolonged QRS, but identifying patients who benefit most requires further study.
Does Cardiac resynchronisation therapy (CRT) improve outcomes in Chronic heart failure (CHF) patients with left ventricular systolic dysfunction and prolonged QRS duration?
Population
Chronic heart failure patients with left ventricular systolic dysfunction and prolonged QRS duration
Comparison
Cardiac resynchronisation therapy with or without implantable cardioverter defibrillator
Design
Review of CRT trial evidence and implantation techniques
Authors
Loading...
Supports CRT consideration in select CHF cases; leaves open need for prospective validation before broader adoption.
Does Cardiac resynchronisation therapy (CRT) improve outcomes in Chronic heart failure (CHF) patients with left ventricular systolic dysfunction and prolonged QRS duration?
CRT is an effective therapy for reducing symptoms and mortality in patients with chronic heart failure, left ventricular systolic dysfunction, and prolonged QRS duration.
Behan et al. (2006) conducted a review in chronic heart failure. Cardiac resynchronisation therapy (CRT) was evaluated. Cardiac resynchronisation therapy reduces symptoms and mortality in chronic heart failure, and an intra-aortic balloon pump can serve as a successful bridge to CRT in end-stage patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: